

January 23, 2025

To,
National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051
(SYMBOL: THYROCARE)

BSE Limited
Phiroze Jeejeeboy Towers
Dalal Street,
Mumbai- 400 001
(SCRIP CODE 539871)

Sub: Press Release on Un-audited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2024.
Ref: Disclosure under Regulation 30 and other applicable regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/ Madam,

Please find enclosed herewith the Press Release on the Un-audited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2024.

We request you to please take the same on record.

For **Thyrocare Technologies Limited**



Ramjee Dorai
Company Secretary and Compliance Officer

Encl: A/a

Press Release

Thyrocare Technologies Limited reports revenue of INR 165.9 Cr in Q3FY25 with a growth of 23% YoY; India's first and only 100% NABL accredited national diagnostic laboratory chain

Revenue

↑ INR 165.9 Cr
23% YoY

EBITDA

↑ INR 41.6 Cr
32% YoY

PAT

↑ INR 18.9 Cr
30% YoY

Navi Mumbai, January 23, 2025

Thyrocare Technologies Limited (hereinafter referred to as “**Thyrocare**” NSE: THYROCARE, BSE: 539871), a leading healthcare diagnostics company, announces their results for the quarter ended December 31, 2024.

Key highlights for Q3FY25:

- India's first and only 100% NABL accredited national diagnostic laboratory chain
- Consolidated revenue increased by 23% year-over-year (YoY) with Pathology and Radiology segments growing by 24% YoY and 13% YoY respectively
- Revenue from franchise surged by 24% YoY, and partnership revenue saw 23% YoY growth
- Consolidated gross margin stood at 73%, and normalized EBITDA margin was 30%
- Standalone reported EBITDA grew by 32% YoY, while PAT increased by 29% YoY
- Consolidated reported EBITDA grew by 32% YoY, while PAT increased by 30% YoY

Consolidated income statement for Q3FY25 and YTD FY25:

INR Crore	Quarter			Year To Date		
	Q3FY25	Q3FY24	YoY	YTD FY25	YTD FY24	YoY
Revenue from operations	165.9	134.7	23%	500.2	417.6	20%
Gross margin	120.7	96.3	25%	358.5	297.5	21%
Normalized EBITDA (before ESOP)	49.3	34.7	42%	144.7	117.1	24%
Reported EBITDA	41.6	31.6	32%	131.9	103.9	27%
Profit after tax	18.9	14.6	30%	68.6	52.5	31%
Key metrics						
Gross margin%	73%	71%		72%	71%	
Normalized EBITDA%	30%	26%		29%	28%	
Reported EBITDA%	25%	23%		26%	25%	
PAT%	11%	11%		13%	12%	

About Thyrocare:

Thyrocare Technologies Limited (NSE: THYROCARE, BSE: 539871) is India's first and foremost advanced fully automated laboratory chain with strong presence PAN India. Thyrocare focuses on providing quality and affordable diagnostic services to laboratories and hospitals. Many laboratories and hospital brands all over India use the comprehensive test profile menu offered by Thyrocare.

Thyrocare has an extensive network of laboratories across PAN India. Thyrocare has a franchise base of 9,100+ and processes 430,000+ diagnostic and screening investigations each night.

Thyrocare is one of the first Indian diagnostic laboratories to obtain internationally renowned quality accreditations including ISO 9001-2000 rating as early as 2001, which was upgraded to ISO 9001:2015 and National Accreditation Board for Testing and Calibration Laboratories (NABL) and College of American Pathologists (CAP) accreditations in 2005.

Safe harbor statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Both the companies assume no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further details please contact:



Company: Thyrocare Technologies Limited

CIN: L85110MH2000PLC123882

Website: www.thyrocare.com

investor_relations@thyrocare.com